These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31066214)

  • 1. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.
    Kostopoulou F; Gabillaud C; Chapiro E; Grange B; Tran J; Bouzy S; Degaud M; Ghamlouch H; Le Garff-Tavernier M; Maloum K; Choquet S; Leblond V; Gabarre J; Lavaud A; Morel V; Roos-Weil D; Uzunov M; Guieze R; Bernard OA; Susin SA; Tournilhac O; Nguyen-Khac F;
    Cancer Med; 2019 Jun; 8(6):3131-3141. PubMed ID: 31066214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
    Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
    Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
    Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia.
    Ma D; Chen Z; Patel KP; Mishra BM; Yao H; Abruzzo LV; Medeiros LJ; Wierda W; Keating M; Sargent R; Luthra R
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S17-24. PubMed ID: 22035742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
    Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
    Nguyen-Khac F; Baron M; Guièze R; Feugier P; Fayault A; Raynaud S; Troussard X; Droin N; Damm F; Smagghe L; Susin S; Leblond V; Dartigeas C; Van den Neste E; Leprêtre S; Bernard OA; Roos-Weil D;
    Br J Haematol; 2024 Aug; 205(2):495-502. PubMed ID: 38654616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex chromosomal aberrations in chronic lymphocytic leukemia are associated with cellular drug and irradiation resistance.
    Koski T; Karhu R; Visakorpi T; Vilpo L; Knuutila S; Vilpo J
    Eur J Haematol; 2000 Jul; 65(1):32-9. PubMed ID: 10914937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain of chromosome 2p in chronic lymphocytic leukemia: significant heterogeneity and a new recurrent dicentric rearrangement.
    Jarosova M; Urbankova H; Plachy R; Papajik T; Holzerova M; Balcarkova J; Pikalova Z; Divoky V; Indrak K
    Leuk Lymphoma; 2010 Feb; 51(2):304-13. PubMed ID: 20078324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
    Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
    Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.
    Fabris S; Mosca L; Cutrona G; Lionetti M; Agnelli L; Ciceri G; Barbieri M; Maura F; Matis S; Colombo M; Gentile M; Recchia AG; Anna Pesce E; Di Raimondo F; Musolino C; Gobbi M; Di Renzo N; Mauro FR; Brugiatelli M; Ilariucci F; Lipari MG; Angrilli F; Consoli U; Fragasso A; Molica S; Festini G; Vincelli I; Cortelezzi A; Federico M; Morabito F; Ferrarini M; Neri A
    Am J Hematol; 2013 Jan; 88(1):24-31. PubMed ID: 23044996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages.
    Chapiro E; Leporrier N; Radford-Weiss I; Bastard C; Mossafa H; Leroux D; Tigaud I; De Braekeleer M; Terré C; Brizard F; Callet-Bauchu E; Struski S; Veronese L; Fert-Ferrer S; Taviaux S; Lesty C; Davi F; Merle-Béral H; Bernard OA; Sutton L; Raynaud SD; Nguyen-Khac F
    Leuk Res; 2010 Jan; 34(1):63-8. PubMed ID: 19406473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.